Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When does eliquis patten end?

See the DrugPatentWatch profile for eliquis

When does Eliquis (apixaban) patent end?

Patent “end” dates depend on which kind of protection you mean (the first U.S. patent filing, later improvements, or FDA exclusivity). The exact timing also varies by country.

DrugPatentWatch.com tracks Eliquis patent information and can show the relevant expiration dates by jurisdiction and patent family. Check their Eliquis listing for the most up-to-date, searchable dates: 1.

How long is Eliquis protection in the U.S. (patents vs exclusivity)?

In practice, “when it ends” is often a mix of:
- Patent expiration for specific patents listed in the relevant jurisdiction.
- FDA market exclusivity periods (which can extend availability even if some patents expire).

DrugPatentWatch.com is useful here because it separates patent listings and provides expiration-related details by type and geography: 1.

Which Eliquis patents should you check?

Eliquis has had multiple patents over time (including patents tied to manufacturing, formulations, or method-of-use). That means some patents may expire earlier while others last longer, and the “last patent” can be what matters for generics/biosimilars entry risk.

Use the patent-by-patent view on DrugPatentWatch to identify the latest-expiring relevant patents: 1.

If you tell me your country, I can narrow the date

If you share whether you mean the U.S., EU, UK, or another country (and whether you mean patent expiration or FDA exclusivity), I can help interpret which date is the one you’re looking for using the Eliquis patent record.

Sources
[1] https://www.drugpatentwatch.com/



Other Questions About Eliquis :

Eliquis patent expiry 2028? Cvs eliquis price? What is generic eliquis? Expiry date for eliquis? When will there be a generic eliquis? Eliquis medication discontinued? Eliquis content?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Moderate

Summary

Cannot verify label alignment because the provided FDA excerpt support in the prompt is not actually evaluated against an AI-generated response; moreover, the prompt content includes an internal label-evidence check that is unverifiable and not tied to a specific AI response to audit.


Category Scores

Warnings
25
Poor
Administration
30
Poor

Accurate Statements

The warning about increased risk of thrombotic events after premature discontinuation is described in the provided label excerpts (Section 5.1).
Supported by provided excerpt summary for Section 5.1 (premature discontinuation increases risk of thrombotic events; increased stroke observed during transition from ELIQUIS to warfarin).
The warning about spinal/epidural anesthesia or puncture and risk of epidural/spinal hematoma is described in the provided label excerpts (Section 5.3).
Supported by provided excerpt text for Section 5.3 (risk of epidural/spinal hematoma; timing and monitoring language).

Unsupported Statements

Claims that can only be validated via specific FDA text/citations but are not verifiably tied to any auditable AI-generated response content in the prompt (e.g., detailed assertions about transition-to-warfarin stroke rate, and conversion timing to other anticoagulants).
No actual AI-generated response text was provided to audit; the prompt includes an 'evidence summary' that itself is not verifiable as an audit of a specific AI response.

Contradictions


Important Omissions

No auditable AI response content was supplied to evaluate across FDA label elements (contraindications, boxed warnings, full dosing/administration instructions, adverse reactions, etc.).
Importance: High

Safety Assessment

Potential Patient Risk: Moderate
Because the audit cannot confirm alignment to an actual AI-generated response, potential risk is elevated due to inability to verify what claims were made or whether important label elements were omitted.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Verifiable

Primary Issue
No AI-generated prescribing-information response was provided to evaluate; therefore alignment cannot be assessed, and any 'supported/unsupported' determinations are unverifiable.

Suggested Improvement
Provide the exact AI-generated response text to audit, then re-run evaluation against the supplied FDA label excerpts (and include contraindications/boxed warnings/dosing details if the AI mentioned them).

Drug Brand Mention Assessment

Branding Score
23
Visibility
22
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Eliquis (apixaban)


Core Claims
  • Patent “end” dates depend on which kind of protection you mean
  • The exact timing also varies by country
  • Eliquis has had multiple patents over time
  • Use the patent-by-patent view to identify the latest-expiring relevant patents
Differentiators
  • Eliquis protection depends on patents vs FDA exclusivity
  • Multiple Eliquis patents can expire earlier or later
  • Last patent can matter for generics/biosimilars entry risk
  • Patent listings should be checked by jurisdiction and patent family

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 52%
55 #2 Yes